ANF
Log in



NOTICEABLE

Collaboration C2TN-IPFN

C2TN-IPFN CollaborationC2TN-IPFN: Rediscovering the past through material analysis

The authenticity of a painting, stained glass or coin can be revealed by a machine that accelerates particles that trigger a radiation that exposes the chemical composition of paints, glass or metals and dates them at an era.

Collaboration CERN-MEDICIS

CERN MEDICIS 2017

CERN-MEDICIS is a spin-off dedicated to R&D in life sciences and medical applications. Relying on the expertise and technology developed at the ISOLDE radioactive ion beam laboratory, at CERN, impinging high-energy (1.4 GeV) proton beams on specific target materials, innovative medical radioisotopes are produced and extracted as ion beams to be separated using an offline mass separator.In this way, highly pure and carrier-free radioisotopes can then be produced, which might be useful for fundamental, pre-clinical and early phase clinical studies, namely in cancer research.

Last Tuesday (13th December), CERN-MEDICIS produced the first batch of radioisotopes, namely Tb-155 using a Ta foils primary target (check links below). Tb-155 is a gamma emitter potentially relevant for the detection of prostate cancer; moreover, being also an Auger-electron emitter, Tb-155 can also be envisaged for cancer therapy. The first batch of collected Tb-155 was then shipped to the Radiopharmaceutical Sciences group of C2TN, where it will be studied under the framework of the project “MEDICIS-produced radioisotope beams for medicine” (Medicis-Promed). Medicis-Promed is a Marie Skłodowska-Curie action leaded by CERN, which integrates the C2TN researchers António Paulo e António Pereira Gonçalves who supervise the PhD students Alice d’Onofrio and Sanjib Chowdhury, respectively.

Detailed information can be found in he following links: www.cern.ch/medicis-promed and http://isolde.web.cern.ch 
https://home.cern/about/updates/2017/12/new-cern-facility-can-help-medical-research-cancer
http://www.horizon2020projects.com/pr-knowledge-innovation/new-cern-facility-help-cancer-research/

 

Interreg project

Picture0

REMEDIO stands for REgenerating mixed-use MED urban communities congested by traffic through Innovative low carbon mobility sOlutions. The project aims at fostering the use of available low carbon transport systems and solutions through the testing of an operational path in the governance and management of high congested roads, a common issue for many middle-sized Mediterranean cities lacking of proper orbital roads or bypasses.
REMEDIO gather institutional partners, as Municipalities and public agency for public transportation or environmental protection, and scientific institutions from 5 different MED countries. One of the territorial challenges for middle sized cities and towns in the Mediterranean area is traffic congestion; REMEDIO focuses on high density areas surrounding the city centers with commercial and directional roads often suffering from traffic jam to the point of becoming wounds in the connectivity of the wide spread city and elements of additional economic crisis and even social exclusion.
REMEDIO is a Testing project funded by Interreg MED Program through the European Regional Developed Fund (ERDF) and is developed in 3 steps.
1. Territorial partners implement soft actions on low carbon mobility solutions;
2. Scientific partners jointly implement an Integrated Modelling Tool to assess the present and future scenarios road performance in terms of energy and freight transport efficiency, noise impact, air pollution, cost & health effects.
3. The city communities are engaged in testing an operational path towards participatory governance such as “horizontal condominiums” or “road contracts” that should lead to higher environmental and mobility performances.

Duration: From November 2016 to April 2019
Total Budget: 2.215.512,50 €
Website: https://remedio.interreg-med.eu/
Contact Person: Marina Almeida Silva |

 

Picture1  Picture2  Picture3  Picture4  Picture5    Picture6  Picture7  Picture8

 

Tribute to the work of Isabel Santos

foto irsantos1

Tribute by Dalton Transactions to our colleague Isabel Santos former President of the Center, on the occasion of her recent retirement, for her contribution to the advancement of science in the field of radiopharmaceutical chemistry,

 

Dalton Transactions w200

Frontiers in radionuclide imaging and therapy, a chemical journey from naturally radioactive elements to targeted theranostic agents 

(place the mouse over the image to magnify the cover page)

 

The high impact journal Dalton Transactions from the Royal Society of Chemistry, which covers all aspects of inorganic and organometallic chemistry, including biological inorganic chemistry, has newly published the themed issue Frontiers in Radionuclide Imaging and Therapy, A chemical journey from naturally radioactive elements to targeted theranostic agents dedicated to the contributions of our colleague Isabel Santos to the advancement of science in the field of radiopharmaceutical chemistry on the occasion of her recent retirement. This special issue guest-edited by our colleague João D. G. Correia and Professors Angela Casini and Chris Orvig from the Universities of Cardif and British Columbia, respectively, covers various relevant aspects of the use of radionuclides in biomedical/clinical applications. Apart from Isabel´s outstanding contributions to the inorganic chemistry community, the fact that she was the first President of the Centre for Nuclear Sciences and Technology (C2TN) is highlighted. Moreover, it is also emphasised that Isabel pioneered in Europe a move towards inclusion of women in science and has been a role model for many of her female students, co-workers and international collaborators.

Congratulations and thank you Isabel.

Pedro Vaz NLO (July 2017)

pedrovazPedro Vaz, Researcher of C2TN, was recently appointed as the new National Liaison Officer (NLO) with the International Atomic Energy Agency. We believe that he will carry out this mission with commitment and contribute to the prestige of Portugal with the IAEA (FCT).
He also became a member of the Editorial Board of the "European Journal of Radiology" (ELSEVIER), since April 2017.

Marta Almeida Leads Two New European Project

ClimACT is a 1.37 M€ project approved within the Low Carbon Economy priority area of the Interreg Sudoe program. The project aims at promoting the transnational cooperation to solve common problems from the Southwest Europe region. More information in this link.

LIFE Index-Air is another 1.37 M€ project approved within the Environment and Resource Efficiency priority area of the LIFE Program. The main objective is to incorporate a database of outdoor and indoor air quality and a package of models to develop an innovative and versatile policy tool that will establish a relation between population exposure to mixtures of PM compounds and emission sources. More information in this link.

IAEA (April 2017)

iaea casestudiesThe IAEA has published online at Neutron/IBA Case Studies a set of 20 case studies about the use of neutrons and accelerators to solve problems of societal relevance. Three of these studies were based on the work of C2TN researchers. 1) Rescuing ancient glazed tiles using neutron tomography (Isabel Prudêncio et al.); 2) The air that we breathe (Marta Almeida et al.); 3) Alloying Kinetics in Contact Metallization for CMOS (Nuno Barradas et al.) These report recognize and reward the merit of C2TN Researchers Nuno Barradas, Marta Almeida and Isabel Prudêncio.